Human CACYBP ELISA Kit (V2LY-0626-LY5543)

Zheng, H., & Chen, C. (2021). Downregulation of CacyBP by CRISPR/dCas9-KRAB Prevents Bladder Cancer Progression. Frontiers in Molecular Biosciences, 8, 557.

Xu, Y. J., Hu, Y. M., Qin, C., Wang, F., Cao, W., Yu, Y. W., ... & He, J. (2021). CacyBP promotes the proliferation and invasion of non-small cell lung cancer. Zhonghua Zhong liu za zhi [Chinese Journal of Oncology], 43(9), 924-931.

Lian, Y. F., Huang, Y. L., Zhang, Y. J., Chen, D. M., Wang, J. L., Wei, H., ... & Huang, Y. H. (2019). CACYBP enhances cytoplasmic retention of P27Kip1 to promote hepatocellular carcinoma progression in the absence of RNF41 mediated degradation. Theranostics, 9(26), 8392.

Kasacka, I., Piotrowska, Ż., Weresa, J., & Filipek, A. (2018). Comparative evaluation of CacyBP/SIP protein, β-catenin, and immunoproteasome subunit LMP7 in the heart of rats with hypertension of different etiology. Experimental Biology and Medicine, 243(15-16), 1199-1206.

Feng, S., Zhou, Q., Yang, B., Li, Q., Liu, A., Zhao, Y., ... & Zhai, H. (2018). The effect of S100A6 on nuclear translocation of CacyBP/SIP in colon cancer cells. Plos one, 13(3), e0192208.

Yan, S., Li, A., & Liu, Y. (2018). CacyBP/SIP inhibits the migration and invasion behaviors of glioblastoma cells through activating Siah1 mediated ubiquitination and degradation of cytoplasmic p27. Cell biology international, 42(2), 216-226.

Topolska-Woś, A. M., Rosińska, S., & Filipek, A. (2017). MAP kinase p38 is a novel target of CacyBP/SIP phosphatase. Amino Acids, 49(6), 1069-1076.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols